Welcome to our dedicated page for Pulsenmore SEC filings (Ticker: PLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulsenmore's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulsenmore's regulatory disclosures and financial reporting.
Pulsenmore Ltd. has expanded its relationship with Clalit Health Services through a new commercial agreement for the Pulsenmore FC at-home follicular monitoring device for women undergoing IVF and fertility preservation in Israel. Following a feasibility trial at Rabin Medical Center that met its protocol criteria, the parties agreed to an 18‑month pilot in which Pulsenmore will sell and market Pulsenmore FC directly to Clalit patients, supported by Beilinson NEXT, Beilinson Medical Center’s virtual hospital platform.
After the pilot, the engagement is set to continue for a five-year term, with Clalit committing to a minimum annual purchase of 2,000 Pulsenmore FC units and the agreement potentially valued at approximately $4.5 million over those five years. Units sold directly by Pulsenmore to Clalit’s patients will count toward the annual minimum, and Clalit may return up to 1,000 units per year and sell units directly to its patients. The companies aim to offer at-home scans with real-time guidance and specialist oversight to reduce repeated in-clinic ultrasound visits during fertility treatment.
Pulsenmore Ltd. filed a report describing that its shares will begin trading on the Nasdaq Capital Market, while continuing to trade on the Tel Aviv Stock Exchange. The company develops home-use ultrasound and telehealth technology that lets physicians supervise prenatal monitoring outside traditional clinics, using proprietary hardware, secure cloud image transmission, and clinical review workflows.
Pulsenmore highlights that it has FDA authorization for its home-use prenatal ultrasound system and describes this as the first and only FDA-authorized home-use prenatal ultrasound system. Management views the Nasdaq listing as a transformative step that may increase visibility and liquidity and help attract a broader, global investor base aligned with its maternal-health focused growth strategy.
FAQ
What is the current stock price of Pulsenmore (PLSM)?
What is the market cap of Pulsenmore (PLSM)?
